1. Home
  2. SBI vs RNTX Comparison

SBI vs RNTX Comparison

Compare SBI & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Western Asset Intermediate Muni Fund Inc

SBI

Western Asset Intermediate Muni Fund Inc

HOLD

Current Price

$7.84

Market Cap

108.9M

Sector

Finance

ML Signal

HOLD

Logo Rein Therapeutics Inc.

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$0.86

Market Cap

89.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SBI
RNTX
Founded
1992
2001
Country
United States
United States
Employees
N/A
10
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.9M
89.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
SBI
RNTX
Price
$7.84
$0.86
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$10.00
AVG Volume (30 Days)
62.0K
579.2K
Earning Date
01-01-0001
05-15-2026
Dividend Yield
4.52%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.51
$0.85
52 Week High
$8.01
$2.18

Technical Indicators

Market Signals
Indicator
SBI
RNTX
Relative Strength Index (RSI) 53.54 39.49
Support Level $7.79 $0.85
Resistance Level $7.90 $1.05
Average True Range (ATR) 0.07 0.07
MACD -0.00 -0.01
Stochastic Oscillator 66.67 4.34

Price Performance

Historical Comparison
SBI
RNTX

About SBI Western Asset Intermediate Muni Fund Inc

Western Asset Intermediate Muni Fd Inc is a diversified closed-end management investment company. The fund's objective is to provide a high level of current income exempt from Federal income taxes. Under normal market conditions, the Fund will invest at least 80% of its total assets in municipal obligations. In addition, under normal market conditions, the Fund will invest at least 80% of its total assets in debt securities that are, at the time of investment, rated investment grade by a nationally recognized statistical rating organization or, if unrated, of equivalent quality as determined by the investment manager.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.

Share on Social Networks: